Participated in PAQ Therapeutics' $39M Series B led by Bayland Capital and MRL Ventures Fund.
PAQ Therapeutics is a biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options
PAQ Therapeutics is a biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options. The company is pioneering a new approach to restoring health and curing disease through autophagy, utilizing their ATTEC technology to develop novel small molecule degraders.